Showing results (151-160 of 186) with videos related to

Sort By:
Pageof 19
European Heart Journal|October 13, 2005
Predictors of mortality and morbidity in patients with chronic heart failureStuart J Pocock, Duolao Wang, Marc A Pfeffer, et al.
The American Journal of Medicine|October 17, 1983
Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertensionE L Michelson, W H Frishman, J E Lewis, et al.
Circulation|August 29, 2007
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failureScott D Solomon, Joanna Dobson, Stuart Pocock, et al.
American Heart Journal|November 19, 2011
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programCono A Ariti, John G F Cleland, Stuart J Pocock, et al.
Lancet (London, England)|August 18, 2009
Albuminuria in chronic heart failure: prevalence and prognostic importanceColette E Jackson, Scott D Solomon, Hertzel C Gerstein, et al.
Circulation|October 7, 2004
Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programScott D Solomon, Duolao Wang, Peter Finn, et al.
The New England Journal of Medicine|March 16, 2006
Feasibility of treating prehypertension with an angiotensin-receptor blockerStevo Julius, Shawna D Nesbitt, Brent M Egan, et al.
European Journal of Heart Failure|February 24, 2007
Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programmeNathaniel M Hawkins, Duolao Wang, John J V McMurray, et al.
Heart (British Cardiac Society)|September 6, 2006
Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programmeN M Hawkins, D Wang, J J V McMurray, et al.
American Heart Journal|April 29, 2006
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialJohn J V McMurray, James B Young, Mark E Dunlap, et al.
Pageof 19